Abstract
Isoniazid (INH) is one of the most commonly used drugs in treatment of human tuberculosis and the most efficient. Although it has been 60 years since isoniazid was introduced in anti-tubercular therapy and despite the simplicity of its chemical structure (C6H7N3O) with few functional groups, its exact mechanism of action, which could account for its specificity and exceptional potency against Mycobacterium tuberculosis and justify all profiles of INH-resistance, remains elusive and debatable. This complexity can find an explanation in the high reactivity of INH and also in the possibility that multiple targets and pathways could co-exist for this medicinal agent. Indeed, since the discovery of isoniazid’s anti-tubercular potency, several propositions for its mode of action have been reported, including its conversion, by a catalase peroxidase within M. tuberculosis, into an active metabolite able, after reaction with NAD, to inhibit an enzyme (InhA) crucial to M. tuberculosis survival. This represents the most consensual mechanism described to date. Nevertheless, none of the proposed mechanisms considered independently can explain the singular and privileged action of the isoniazid structure on the tubercle bacillus, or all the profiles of resistance. The aim of this paper is to reconsider the literature reporting the different modes of action described for isoniazid in the light of the present and most relevant knowledge, with special attention to understanding the molecular mechanistic aspects of the drug’s action.
Keywords: Isoniazid, KatG, mechanism of action, Mycobacterium tuberculosis, pro-drug, radicals, isoniazid resistances.
Current Medicinal Chemistry
Title:Isoniazid: an Update on the Multiple Mechanisms for a Singular Action
Volume: 20 Issue: 35
Author(s): V. Bernardes-Génisson, C. Deraeve, A. Chollet, J. Bernadou and G. Pratviel
Affiliation:
Keywords: Isoniazid, KatG, mechanism of action, Mycobacterium tuberculosis, pro-drug, radicals, isoniazid resistances.
Abstract: Isoniazid (INH) is one of the most commonly used drugs in treatment of human tuberculosis and the most efficient. Although it has been 60 years since isoniazid was introduced in anti-tubercular therapy and despite the simplicity of its chemical structure (C6H7N3O) with few functional groups, its exact mechanism of action, which could account for its specificity and exceptional potency against Mycobacterium tuberculosis and justify all profiles of INH-resistance, remains elusive and debatable. This complexity can find an explanation in the high reactivity of INH and also in the possibility that multiple targets and pathways could co-exist for this medicinal agent. Indeed, since the discovery of isoniazid’s anti-tubercular potency, several propositions for its mode of action have been reported, including its conversion, by a catalase peroxidase within M. tuberculosis, into an active metabolite able, after reaction with NAD, to inhibit an enzyme (InhA) crucial to M. tuberculosis survival. This represents the most consensual mechanism described to date. Nevertheless, none of the proposed mechanisms considered independently can explain the singular and privileged action of the isoniazid structure on the tubercle bacillus, or all the profiles of resistance. The aim of this paper is to reconsider the literature reporting the different modes of action described for isoniazid in the light of the present and most relevant knowledge, with special attention to understanding the molecular mechanistic aspects of the drug’s action.
Export Options
About this article
Cite this article as:
Bernardes-Génisson V., Deraeve C., Chollet A., Bernadou J. and Pratviel G., Isoniazid: an Update on the Multiple Mechanisms for a Singular Action , Current Medicinal Chemistry 2013; 20 (35) . https://dx.doi.org/10.2174/15672050113109990203
DOI https://dx.doi.org/10.2174/15672050113109990203 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting InhA, the FASII Enoyl-ACP Reductase: SAR Studies on Novel Inhibitor Scaffolds
Current Topics in Medicinal Chemistry Application of Sugar-Base Anhydro Bridge for Modification of Nucleosides in the 2’- and/or 3’-Positions - Revisited
Current Organic Chemistry Drug Delivery Systems: A Few Examples of Applications, Drug Cargoes, and Administration Routes
Current Pharmaceutical Design Targeting the Human Macrophage with Combinations of Drugs and Inhibitors of Ca2+ and K+ Transport to Enhance the Killing of Intracellular Multi-Drug Resistant Mycobacterium tuberculosis (MDR-TB) - a Novel, Patentable Approach to Limit the Emergence of XDR-TB
Recent Patents on Anti-Infective Drug Discovery Solid Lipid Nanoparticles: A Potential Approach for Drug Delivery System
Nanoscience & Nanotechnology-Asia Editorial: Applications of Medicinal Bioinorganic Chemistry
Current Medicinal Chemistry Design of multifunctional nanocarriers for delivery of anti-cancer therapy
Current Pharmaceutical Design Patents in Targets and Drugs for Unbalanced Cytokine and Chemokine Network Mediated Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Genetics and Vaccines in the Era of Personalized Medicine
Current Genomics Antimalarial Drugs and their Useful Therapeutic Lives: Rational Drug Design Lessons from Pleiotropic Action of Quinolines and Artemisinins
Current Drug Discovery Technologies Lectin Techniques for Glycoproteomics
Current Proteomics Nanoemulsion-Based Transdermal Drug Delivery System for the Treatment of Tuberculosis
Recent Patents on Anti-Infective Drug Discovery Accessing Highly-Halogenated Flavanones Using Protic Ionic Liquids and Microwave Irradiation
Current Organic Chemistry Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry B-Cells and the Use of Non-Human Primates for Evaluation of HIV Vaccine Candidates
Current HIV Research Newest Strategies in the Search for Bioactive Saponins from the Tropical Plant Biodiversity
Current Drug Delivery Lipid-Specific Immune Responses Against Tuberculosis: From Basic Science to Medical Applications
Current Immunology Reviews (Discontinued) Animal Venom Peptides: Potential for New Antimicrobial Agents
Current Topics in Medicinal Chemistry Anti-Tuberculosis Drug Induced Hepatotoxicity and Genetic Polymorphisms in Drug-metabolizing Genes
Current Pharmacogenomics The Indian Pediatric HIV Epidemic: A Systematic Review
Current HIV Research